Form 4: Harmony Biosciences CEO Exercises Stock Options and Receives Restricted Stock Units

Harmony Biosciences CEO, Jeffrey M. Dayno, exercised stock options and received restricted stock units, resulting in changes to his beneficial ownership of company stock.

Summary

• On January 24, 2025, Harmony Biosciences CEO Jeffrey M. Dayno exercised 10,500 restricted stock units, receiving 10,500 shares of common stock.
• The company withheld 4,567 shares to cover income tax obligations at a price of $38.01 per share.
• This resulted in a net increase of 5,933 shares of common stock held directly by Mr. Dayno.
• On January 25, 2025, Mr. Dayno was granted 180,000 stock options and 52,000 restricted stock units.
• The stock options have an exercise price of $38.01 and vest over four years.
• The restricted stock units vest over four years.

Sentiment

Score: 7

Explanation: The document reflects standard executive compensation practices, which are generally viewed positively as they align management interests with shareholders. There are no indications of negative events or concerns.

Positives

• The granting of stock options and restricted stock units to the CEO aligns his interests with those of the shareholders.
• The vesting schedule of the options and restricted stock units encourages long-term commitment from the CEO.

Risks

• The exercise of stock options and vesting of restricted stock units could potentially dilute existing shareholders' ownership if not managed carefully.

Industry Context

This type of stock option and restricted stock unit grant is a common practice for incentivizing and retaining key executives in publicly traded companies.

Comparison to Industry Standards

• Stock option and restricted stock unit grants are standard compensation practices for CEOs in publicly traded companies, such as those in the biotechnology and pharmaceutical sectors.
• Companies like BioMarin Pharmaceutical Inc. and Vertex Pharmaceuticals Incorporated also use similar equity-based compensation plans for their executives.
• The vesting schedules of four years are also typical in the industry, aligning executive compensation with long-term company performance.

Stakeholder Impact

• Shareholders may view the stock option and restricted stock unit grants positively as they incentivize the CEO to increase the company's value.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

stock options, restricted stock units, beneficial ownership, CEO, equity, Harmony Biosciences, HRMY, insider trading